AnchorDx is a technology company.
AnchorDx has raised $28.0M across 1 funding round.
AnchorDx has raised $28.0M in total across 1 funding round.
AnchorDx has raised $28.0M in total across 1 funding round.
AnchorDx's investors include 6 Dimensions Capital.
AnchorDx is a precision diagnostics company specializing in early cancer detection through ctDNA high-throughput methylation sequencing technology.[2][3] Founded in 2015 and headquartered in Guangzhou, China, with R&D centers in China and the US, it develops non-invasive products like "a tube of blood" and "a tube of urine" tests covering over 70% of high-incidence cancers, including lung, breast, digestive, and urinary system cancers, for screening, early diagnosis, recurrence monitoring, and companion diagnostics.[1][2][3] AnchorDx serves oncologists, hospitals, and patients by solving the challenge of detecting cancers at early stages when treatments are most effective, leveraging proprietary technologies such as AnchorIRIS® for DNA methylation profiling and an AI platform for lung cancer.[2][3][4] The company has shown strong growth through partnerships (e.g., with DiaCarta and Illumina), clinical trials like the Bell Program, product launches such as UriFind® for bladder cancer, and $43 million in Series A+ and B financing.[1][2]
AnchorDx was officially established in 2015 in Guangzhou International Bio Island, pioneering ctDNA methylation sequencing for tumor early detection in China.[2][3] Key founders and leaders include a global genetic technology expert and former Illumina chief scientist (employee #23), who led high-throughput sequencing developments and returned to China for precision medicine; Marina, with 20+ years in genomic technologies from Illumina, Grail, and Thermo Fisher; and other specialists in liquid biopsy and companion diagnostics.[2] The idea emerged from advancing non-invasive detection via blood and urine, starting with Guangzhou AnchorDx Medical Laboratory and early studies presented at CSCO and AACR conferences (first in China and world for certain methylation applications).[2] Pivotal moments include Series A financing ($5M) in 2015, strategic ties with Illumina and Fred Hutchinson Cancer Center, the Bell Program clinical trials with Academician Nanshan Zhong, LDT qualification as China's first NGS clinical lab, and $38M in A+ and B rounds.[2]
AnchorDx rides the liquid biopsy wave, leveraging ctDNA methylation for non-invasive early cancer detection amid rising global cancer burdens and demand for personalized medicine.[1][2][3] Timing aligns with advances in high-throughput sequencing (e.g., Illumina roots) and AI-driven diagnostics, enabling population-scale screening where traditional methods like imaging fall short.[2][4] Market forces favoring it include China's precision medicine push, regulatory nods (e.g., national genetic testing center), and partnerships accelerating global reach amid aging populations and high lung/colorectal cancer rates.[2] It influences the ecosystem by publishing in top journals (e.g., Journal of Clinical Investigation, NPJ Breast Cancer), licensing patents, and validating methylation in prospective trials, paving the way for pan-cancer tools and reducing late-stage diagnoses.[2][3][4]
AnchorDx is poised for global expansion via partnerships like DiaCarta and ongoing trials (e.g., Thunder Project, Angel-2), potentially launching more pan-cancer blood/urine tests and scaling its AI platform.[1][3] Trends like multi-omics integration, regulatory harmonization (e.g., FDA/CLIA), and AI enhancements will shape its path, boosting sensitivity for minimal residual disease monitoring. Its influence may evolve from China pioneer to worldwide leader, commercializing IP amid a $10B+ liquid biopsy market, building on methylation's edge over mutation-based rivals for earlier detection. This positions AnchorDx to transform "better diagnostics, better life" from vision to standard care.[2][3]
AnchorDx has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Series B in November 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2017 | $28.0M Series B | 6 Dimensions Capital |